Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 3000 of 3284 entries
View as:

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01597388 Org: User:
Start: 05/08/12 End: 09/05/28 Due: 09/05/29

Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care

Phase: N/A Priority: Normal
NCT ID: NCT01105325 Org: User:
Start: 04/30/10 End: 03/31/11 Due: 03/31/12

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

Phase: N/A Priority: Normal
NCT ID: NCT01103622 Org: User:
Start: 06/30/10 End: 12/31/10 Due: 12/31/11

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Phase: N/A Priority: Normal
NCT ID: NCT05939128 Org: User:
Start: 06/30/23 End: 09/30/27 Due: 09/30/28

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

Phase: N/A Priority: Normal
NCT ID: NCT00242736 Org: User:
Start: 10/31/05 End: 01/31/06 Due: 01/31/07

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Phase: N/A Priority: Normal
NCT ID: NCT03022409 Org: User:
Start: 09/18/17 End: 01/20/21 Due: 01/20/22

Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00542594 Org: User:
Start: 11/30/05 End: 06/30/11 Due: 06/30/12

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

Phase: N/A Priority: Normal
NCT ID: NCT04191304 Org: User:
Start: 07/20/20 End: 04/23/27 Due: 04/23/28

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT02511106 Org: User:
Start: 10/21/15 End: 01/31/29 Due: 01/31/30

PHARMO Institute Seroquel Safety Study

Phase: N/A Priority: Normal
NCT ID: NCT01342120 Org: User:
Start: 09/30/10 End: 11/30/10 Due: 11/30/11

Be SMART NIS, Moderate to Servere Asthma Patient Observation

Phase: N/A Priority: Normal
NCT ID: NCT00514787 Org: User:
Start: - End: - Due: -

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03421353 Org: User:
Start: 02/07/18 End: 03/28/24 Due: 03/28/25

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

Phase: N/A Priority: Normal
NCT ID: NCT06194825 Org: User:
Start: 12/01/23 End: 01/21/27 Due: 01/21/28

Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT01544608 Org: User:
Start: 07/31/12 End: 12/31/12 Due: 12/31/13

307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00255502 Org: User:
Start: 07/31/02 End: - Due: -

Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT02281357 Org: User:
Start: 02/19/15 End: 09/07/17 Due: 09/07/18

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

Phase: N/A Priority: Normal
NCT ID: NCT04532645 Org: User:
Start: 01/07/21 End: 09/27/24 Due: 09/27/25

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Phase: N/A Priority: Normal
NCT ID: NCT03140072 Org: User:
Start: 05/10/17 End: 08/23/17 Due: 08/23/18

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03932331 Org: User:
Start: 04/29/20 End: 06/24/26 Due: 06/24/27

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase: N/A Priority: Normal
NCT ID: NCT00378482 Org: User:
Start: 03/05/07 End: 10/27/23 Due: 10/27/24

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT04236414 Org: User:
Start: 01/14/20 End: 02/04/25 Due: 02/04/26

Forxiga HF General Drug Use-Results Study

Phase: N/A Priority: Normal
NCT ID: NCT04865406 Org: User:
Start: 05/10/21 End: 08/22/24 Due: 08/22/25

Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00960349 Org: User:
Start: 08/31/09 End: 03/31/11 Due: 03/31/12

Efficacy of Esomeprazole in Patients With Frequent Heartburn

Phase: N/A Priority: Normal
NCT ID: NCT01370538 Org: User:
Start: 08/31/11 End: 10/31/11 Due: 10/31/12

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06138795 Org: User:
Start: 11/20/23 End: 05/30/25 Due: 05/30/26